Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ayman Askari

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Saudi Medical Journal|October 5, 2016
Skin response to pressure and ageingP Thirumalaikolundusubramanian, Ayman Askari
Cytokine|April 15, 2014
Orphan receptor GPR15/BOB is up-regulated in rheumatoid arthritisAlison Cartwright, Caroline Schmutz, Ayman Askari, et al.
Case Reports in Pulmonology|September 1, 2022
Spontaneous Pneumothorax in a Patient with Systemic Lupus Erythematosus and Recent Infection with CoronavirusNicholas Graves, Julia Flint, Amol Sagdeo, et al.
Journal of Translational Medicine|June 5, 2014
Intra-articular injection of mesenchymal stem cells leads to reduced inflammation and cartilage damage in murine antigen-induced arthritisOksana Kehoe, Alison Cartwright, Ayman Askari, et al.
Advances in Therapy|November 18, 2025
Clinical and Real-World Evidence on Etanercept Biosimilar Switching: A Narrative Literature Review of Efficacy and SafetyMarc Schmalzing, Ayman Askari, Giampiero Girolomoni, et al.
BMC Medicine|February 14, 2023
Approaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active diseasePeter C Taylor, Ayman Askari, Ernest Choy, et al.
Rheumatology (Oxford, England)|August 16, 2014
Factors influencing work disability in psoriatic arthritis: first results from a large UK multicentre studyWilliam Tillett, Gavin Shaddick, Ayman Askari, et al.
Immunotherapy|May 12, 2025
Assessing real-world treatment with SDZ ETN (an etanercept biosimilar) in people with rheumatic diseases included in the COMPACT study: a plain language summaryMarc Schmalzing, Herbert Kellner, Ayman Askari, et al.
Rheumatology (Oxford, England)|December 26, 2016
Effect of anti-TNF and conventional synthetic disease-modifying anti-rheumatic drug treatment on work disability and clinical outcome in a multicentre observational cohort study of psoriatic arthritisWilliam Tillett, Gavin Shaddick, Amelia Jobling, et al.
Advances in Therapy|November 11, 2023
Real-World Effectiveness and Safety of SDZ ETN, an Etanercept Biosimilar, in Patients with Rheumatic Diseases: Final Results from Multi-Country COMPACT StudyMarc Schmalzing, Herbert Kellner, Ayman Askari, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Saudi Medical Journal|October 5, 2016
Skin response to pressure and ageingP Thirumalaikolundusubramanian, Ayman Askari
Cytokine|April 15, 2014
Orphan receptor GPR15/BOB is up-regulated in rheumatoid arthritisAlison Cartwright, Caroline Schmutz, Ayman Askari, et al.
Case Reports in Pulmonology|September 1, 2022
Spontaneous Pneumothorax in a Patient with Systemic Lupus Erythematosus and Recent Infection with CoronavirusNicholas Graves, Julia Flint, Amol Sagdeo, et al.
Journal of Translational Medicine|June 5, 2014
Intra-articular injection of mesenchymal stem cells leads to reduced inflammation and cartilage damage in murine antigen-induced arthritisOksana Kehoe, Alison Cartwright, Ayman Askari, et al.
Advances in Therapy|November 18, 2025
Clinical and Real-World Evidence on Etanercept Biosimilar Switching: A Narrative Literature Review of Efficacy and SafetyMarc Schmalzing, Ayman Askari, Giampiero Girolomoni, et al.
BMC Medicine|February 14, 2023
Approaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active diseasePeter C Taylor, Ayman Askari, Ernest Choy, et al.
Rheumatology (Oxford, England)|August 16, 2014
Factors influencing work disability in psoriatic arthritis: first results from a large UK multicentre studyWilliam Tillett, Gavin Shaddick, Ayman Askari, et al.
Immunotherapy|May 12, 2025
Assessing real-world treatment with SDZ ETN (an etanercept biosimilar) in people with rheumatic diseases included in the COMPACT study: a plain language summaryMarc Schmalzing, Herbert Kellner, Ayman Askari, et al.
Rheumatology (Oxford, England)|December 26, 2016
Effect of anti-TNF and conventional synthetic disease-modifying anti-rheumatic drug treatment on work disability and clinical outcome in a multicentre observational cohort study of psoriatic arthritisWilliam Tillett, Gavin Shaddick, Amelia Jobling, et al.
Advances in Therapy|November 11, 2023
Real-World Effectiveness and Safety of SDZ ETN, an Etanercept Biosimilar, in Patients with Rheumatic Diseases: Final Results from Multi-Country COMPACT StudyMarc Schmalzing, Herbert Kellner, Ayman Askari, et al.
Pageof 1